Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1

Cardiovascular Research

Volumn 99, Issue 4, 2013, Pages 769-779

  Rahmutula, Dolkun ^a   Marcus, Gregory M ^a   Wilson, Emily E ^a   Ding, Chun Hua ^b   Xiao, Yuanyuan ^a   Paquet, Agnes C ^a   Barbeau, Rebecca ^a   Barczak, Andrea J ^a   Erle, David J ^a   Olgin, Jeffrey E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

Atrial fibrillation; Cardiac fibrosis; Gene expression; Heart failure; Transforming growth factor beta1

Indexed keywords

RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPLANT; FIBROSIS; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN HEART SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA ANALYSIS; SELECTIVE ATRIAL FIBROSIS; SURGICAL PATIENT; TRANSGENIC MOUSE;

ATRIAL FIBRILLATION; CARDIAC FIBROSIS; GENE EXPRESSION; HEART FAILURE; TRANSFORMING GROWTH FACTOR-BETA1;

ANIMALS; ATRIAL FIBRILLATION; FIBROSIS; HEART ATRIA; HUMANS; MICE; MICE, TRANSGENIC; MINK; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84883233816     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt074     Document Type: Article

References (46)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001;37:371-378.
2. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009;119:606-618.
3. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrialventricular remodeling differences. Circulation 2008;117:1630-1641.
4. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226.
5. Lee KW, Everett TH 4th, Rahmutula D, Guerra JM, Wilson E, Ding C et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006;114:1703-1712.
6. Verheule S, Sato T, Everett T, Engle SK, Otten D, Rubart-von der Lohe M et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-1465.
7. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004;90:400-405.
8. Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004;63:236-244.
9. Marcus GM, Yang Y, Varosy PD, Ordovas K, Tseng ZH, Badhwar N et al. Regional left atrial voltage in patients with atrial fibrillation. Heart Rhythm 2007;4:138-144.
10. Cardin S, Libby E, Pelletier P, Le Bouter S, Shiroshita-Takeshita A, Le Meur N et al. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res 2007;100:425-433.
11. On YK, Jeon ES, Lee SY, Shin DH, Choi JO, Sung J et al. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg 2009;137:1515-1520.
12. Kim SK, Pak HN, Park JH, Ko KJ, Lee JS, Choi JI et al. Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace 2009;11: 1632-1638.
13. Behnes M, Hoffmann U, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M et al. Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol 2011;100:335-342.
14. Kim SK, Park JH, Kim JY, Choi JI, Joung B, Lee MH et al. High plasma concentrations of transforming growth factor-beta and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. Circ J 2011;75:557-564.
15. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96: 1180-1184.
16. Verheule S, Wilson E, Banthia S, Everett TH 4th, Shanbhag S, Sih HJ et al. Directiondependent conduction abnormalities in a canine model of atrial fibrillation due to chronic atrial dilatation. Am J Physiol Heart Circ Physiol 2004;287:H634-H644.
17. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, Jing S et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factorbeta( 1) transgene in the heart. Circ Res 2000;86:571-579.
18. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994;216:276-284.
19. Cao L, Wu J, Gardner DG. Atrial natriuretic peptide suppresses the transcription of its guanylyl cyclase-linked receptor. J Biol Chem 1995;270:24891-24897.
20. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007;98: 127-133.
21. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999;270:41-49.
22. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm 2010;7:1438-1445.
23. Salama G, Kanai A, Efimov IR. Subthreshold stimulation of Purkinje fibers interrupts ventricular tachycardia in intact hearts. Experimental study with voltage-sensitive dyes and imaging techniques. Circ Res 1994;74:604-619.
24. Bayly PV, KenKnight BH, Rogers JM, Hillsley RE, Ideker RE, Smith WM. Estimation of conduction velocity vector fields from epicardial mapping data. IEEE Trans Biomed Eng 1998;45:563-571.
25. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article3.
26. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002; 105:2672-2678.
27. He X, Gao X, Peng L,Wang S, Zhu Y, Ma H et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res 2011;108:164-175.
28. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2002;282:H1685-H1696.
29. Sanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003;108:1461-1468.
30. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95.
31. Kistler PM, Sanders P, Dodic M, Spence SJ, Samuel CS, Zhao C et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006;27:3045-3056.
32. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z et al. Effects of angiotensinconverting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608-2614.
33. Cha TJ, Ehrlich JR, Zhang L, Shi YF, Tardif JC, Leung TK et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 2004;109:412-418.
34. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008;155:303-309.
35. Li JY, Lai YJ, Yeh HI, Chen CL, Sun S, Wu SJ et al. Atrial gap junctions, NF-kappaB and fibrosis in patients undergoing coronary artery bypass surgery: the relationship with postoperative atrial fibrillation. Cardiology 2009;112:81-88.
36. Everett TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007;4:S24-S27.
37. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP,Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925.
38. Spach MS. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ Res 2007;101:743-745.
39. Spach MS, Boineau JP. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. Pacing Clin Electrophysiol 1997;20:397-413.
40. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 2004;95:1167-1173.
41. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002;4:599-604.
42. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 2005;53:1245-1256.
43. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002;14:681-685.
44. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003;81:355-363.
45. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RD et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-461.
46. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008;359:158-165.